BofA analyst Jason Gerberry raised the firm’s price target on Jazz Pharmaceuticals (JAZZ) to $216 from $213 and keeps a Buy rating on the shares. Jazz reported a 9% revenue miss driven by seasonality factors and one fewer shipping week in the oncology segment, but the firm doesn’t see the Q1 update as thesis changing given the quarter is historically soft, thus it only trims its FY25 forecast 2%, the analyst tells investors in a post-earnings note. The firm rolled its valuation forward to be based on its 2026 EBITDA outlook from 2025 previously, the analyst noted.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JAZZ:
- Jazz Pharmaceuticals price target lowered to $166 from $183 at Morgan Stanley
- Optimistic Growth Outlook for Jazz Pharmaceuticals Amid Strategic Product Focus and Pipeline Catalysts
- Positive Outlook for Jazz Pharmaceuticals: Buy Rating Affirmed Amid Strategic Moves and Upcoming Catalysts
- Jazz Pharmaceuticals: Buy Rating Affirmed Amid Growth Potential and Transformative Catalysts
- Jazz Pharmaceuticals Reports Q1 2025 Financial Results